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Abstract
Objective
To investigate whether chronic traumatic encephalopathy (CTE) and CTE with amyotrophic
lateral sclerosis (CTE-ALS) exhibit features previously observed in other tauopathies of
pathologic phosphorylation of microtubule-associated protein tau at Thr175 (pThr175 tau) and
Thr231 (pThr231 tau), and glycogen synthase kinase–3β (GSK3β) activation, and whether these
pathologic features are a consequence of traumatic brain injury (TBI).
Methods
Tau isoform expression was assayed by western blot in 6 stage III CTE cases. We also used
immunohistochemistry to analyze 5 cases each of CTE, CTE-ALS, and 5 controls for expression of activated GSK3β, pThr175 tau, pThr231 tau, and oligomerized tau within spinal cord
tissue and hippocampus. Using a rat model of moderate TBI, we assessed tau pathology and
phospho-GSK3β expression at 3 months postinjury.
Results
CTE and CTE-ALS are characterized by the presence of all 6 tau isoforms in both soluble and
insoluble tau isolates. Activated GSK3β, pThr175 tau, pThr231 tau, and oligomerized tau protein
expression was observed in hippocampal neurons and spinal motor neurons. We observed tau
neuronal pathology (ﬁbrillar inclusions and axonal damage) and increased levels of pThr175 tau
and activated GSK3β in moderate TBI rats.
Conclusions
Pathologic phosphorylation of tau at Thr175 and Thr231 and activation of GSK3β are features of
the tauopathy of CTE and CTE-ALS. These features can be replicated in an animal model of
moderate TBI.
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Glossary
AD = Alzheimer disease; ALS = amyotrophic lateral sclerosis; ALSci = amyotrophic lateral sclerosis with cognitive impairment;
ANOVA = analysis of variance; CTE = chronic traumatic encephalopathy; GSK3β = glycogen synthase kinase–3β; NFT =
neuroﬁbrillary tangle; pGSK3β = phospho–glycogen synthase kinase–3β; pThr175 tau = tau phosphorylated at threonine 175;
pThr231 tau = tau phosphorylated at threonine 231; RT = room temperature; TBI = traumatic brain injury.

Chronic traumatic encephalopathy (CTE) is a fatal neurodegenerative disease that is closely associated with
traumatic brain injury (TBI).1 Although TBI is typically
associated with elite athletes, it also occurs as a result of
both recreational and non-sport-related accidents.2,3 While
there remains some controversy, a relationship between
TBI and amyotrophic lateral sclerosis (ALS) has been observed, with between 4% and 6% of patients with CTE
demonstrating either clinical or neuropathologic features
consistent with a diagnosis of ALS.4–7 CTE is an aﬀective,
behavioral, or cognitive disorder associated with repetitive
head trauma that has a characteristic pattern of widespread
neuronal and glial microtubule-associated tau (tau protein)
deposition.8 In patients with concomitant ALS (CTEALS), motor neuron degeneration is also observed, including the presence of TDP-43 neuronal cytoplasmic
inclusions.9
The presence of a tauopathy in CTE and CTE-ALS raises the
potential of a shared pathophysiology with ALS with cognitive impairment (ALSci), where tau is pathologically
phosphorylated at threonine 175 (pThr175 tau) and threonine 231 (pThr231 tau), yielding pathogenic tau oligomers
that subsequently assemble into insoluble pathologic tau
ﬁbrils.1,10–15 In this process, pThr175 tau induces phosphorylation and activation of glycogen synthase kinase–3β
(GSK3β), which in turn promotes tau phosphorylation at
Thr231.16 Supporting the key role of pThr175, pThr175 tau has
only been observed in pathologic states, including a broad
range of tauopathies.10,13,17
To date, there have been no detailed studies of the phosphorylation state of tau in either CTE or CTE-ALS. Given
this, we examined postmortem archival tissues from
patients with CTE and patients with CTE-ALS for pThr175,
pThr 231, the active isoform of GSK3β (phospho-GSK3β
[pGSK3β]), and tau oligomerization. We also examined
whether this process can be triggered by moderate TBI in
a rodent.

Methods
Standard protocol approvals, registrations,
and patient consents
All studies on human tissues were conducted in accordance
with the institutional ethics board standards at University
Hospital (London, Canada) and Boston University School of
Medicine (Massachusetts). All animal protocols were
Neurology.org/N

approved by the University of Western Ontario Animal Care
Committee in accordance with the Canadian Council on
Animal Care.
CTE and CTE-ALS studies
Microscope slides with 6-μm-thick hippocampal and spinal
cord sections from neuropathologically conﬁrmed cases of
CTE (n = 5) and CTE-ALS (n = 5) in addition to 5 control
cases with no neuropathologic evidence of a neurodegenerative disease state (cases 7–19) were used for immunohistochemical studies. An additional 6 cases (cases 1–6)
were obtained as frozen tissue from anterior cingulate and
temporal pole. All tissue and slides were obtained from the
Veterans Aﬀairs–Boston University–Concussion Legacy
Foundation brain bank and were neuropathologically
diagnosed as stage III CTE.8,18 Demographic data are
summarized in table e-1 (http://links.lww.com/
WNL/A99).
Tau fractionation and western blot

Tau protein was isolated from the anterior cingulate gyrus and
the temporal pole of 6 stage III CTE cases and a single Alzheimer disease (AD) case as a control. Tau isolation, fractionation, dephosphorylation, and western blot were
conducted as previously reported (e-Methods, http://links.
lww.com/WNL/A100).19,20
After transfer to nitrocellulose membranes, samples were
probed for total tau with rabbit anti-tau T14/T46 antibodies
(Thermo-Fisher, Burlington, Canada). After horseradish
peroxidase–conjugated secondary antibody labeling, blots
were visualized using enhanced chemiluminescence (PerkinElmer, Waltham, MA).
Immunohistochemistry

Six-micrometer paraﬃn-embedded sections from the hippocampus and spinal cord were analyzed for all cases. Immunohistochemistry was conducted using a series of antibodies
(complete details in table e-2, http://links.lww.com/WNL/
A99) that recognized pThr175 tau (21st Century, Marlboro,
MA), pThr231 tau (Thermo-Fisher), and oligomeric tau (T22;
EMD Millipore, Billerica, CA), and activated GSK3β
(pTyr216; BD Biosciences, Mississauga, Canada). Antigen
retrieval (10 mM sodium citrate, 0.05% Tween 20 pH 6.0)
was conducted for all antibodies using a pressure cooker
(2100 Retriever; Aptum Biologics, Southampton, UK, table
e-2). Endogenous peroxidase was quenched with 3% hydrogen peroxide (VWR, Mississauga, Canada). Primary antibody
incubation was performed at 4°C overnight in blocking buﬀer
Neurology | Volume 90, Number 5 | January 30, 2018

e381

(5% bovine serum albumin, 0.3% Triton-X 100 in 1 ×
phosphate-buﬀered saline). After washing, secondary antibody (1:200 biotinylated immunoglobulin G) incubation was
performed for 1 hour at room temperature (RT) in blocking
buﬀer.
Antigen
Antibody complex was visualized with horseradish peroxidase according to the manufacturer’s instructions (Vectastain ABC kit, Vector Laboratories, Burlingame, CA),
followed by substrate development with 3,39-diaminobenzidine (DAB). Counterstaining was performed
using Harris hematoxylin.
The extent of pathology was described semiquantitatively
as previously reported using visualization with a 20× objective under light microscopy (Olympus BX45; Center
Valley, PA).10,21 The semiquantitative scale was applied as
follows: − = none; ± = fewer than 5; + = fewer than 10; ++ =
more than 20 with scattered distribution; +++ = more than
20 but with locally dense distribution; ++++ = more than
20 with a diﬀuse distribution as observed for each 20×
objective ﬁeld. In addition, the case positive ratio was deﬁned for each antibody as the number of cases showing any
pathology (± or more) compared to the total number of
cases stained. Spinal cord pathology was assessed by a binary scale due to the sparse nature of pathology where + =
pathology present and − = pathology absent.

to reduce artefactual tau pathology.22,23 After 24 hours of
ﬁxation, tissue was embedded in paraﬃn.
Western blots

Immunoblots were also performed using isolates from
6 moderate TBI rats and 4 age-matched controls
(e-Methods, links.lww.com/WNL/A100). Brieﬂy, brain
tissue was homogenized in RIPA buﬀer containing protease
and phosphatase inhibitors followed by concentration determination by modiﬁed Bradford assay (Bio-Rad, Hercules, CA). After immunoprecipitation of brain lysate for total
tau (T46 antibody), the entire immunoprecipitation yield
was run as a western blot (e-Methods). After transfer to
nitrocellulose membrane, blots were probed with rabbit
anti-pThr175 tau. Gels were stripped for 30 minutes at 50°C
and reprobed with rabbit anti–total tau (Abcam, Cambridge, UK). pGSK3β studies were performed on total
brain lysate with mouse anti-GSK3β pTyr216 followed by
reprobing with mouse anti-total GSK3β (BD Biosciences).
Blots were visualized digitally by enhanced chemiluminescence (Perkin-Elmer) (Bio-Rad Chemidoc MP
imaging system and acquired with ImageLab 5.2.1 software). Densitometry was conducted in ImageJ.
Immunohistochemistry

Six moderate TBI and 3 age-matched control rat brains were
cut to 5–6 μm thickness and stained for pThr175 tau, pThr231
tau, and pTyr216 GSK3β using the same antibodies and protocol used in human cases.

Colocalizations and fluorescence staining

e382

Double labeling was performed on sections from the hippocampus from one case per double-label experiment. Tau
protein was probed with pThr175 or oligomeric tau (T22)
rabbit primary antibody overnight at 4°C and Alexa Fluor
goat anti-rabbit 488 nm secondary (Thermo-Fisher) for 1
hour at RT. Rabbit anti-tau pThr231 antibody was labeled
using a Zenon primary antibody labeling kit with Alexa
Fluor 555 nm dye (Thermo-Fisher) and probed for 1 hour
at RT. Slides were visualized within 24 hours by confocal
imaging on a Zeiss (Oberkochen, Germany) LSM 510
Meta NLO multiphoton confocal microscope. For colocalizations with pGSK3β, staining was performed with
mouse anti-pTyr216 GSK3β antibody (BD Biosciences)
followed by secondary labeling with goat anti-mouse Alexa
Fluor 633 nm (Invitrogen, Carlsbad, CA).

Statistical analysis
Statistical analyses were conducted using SigmaPlot 10.0
software. A one-way analysis of variance (ANOVA) was
conducted following a Shapiro-Wilk test for normality. Post
hoc Tukey test was conducted and a p value of 0.05 or lower
was considered signiﬁcant.

In vivo studies
Twelve adult female Sprague-Dawley rats were subjected to
a 5-mm-diameter craniotomy followed by a single moderate
head trauma (3.5 m/s, 2 mm deep, dwell time of 500 ms)
using a cortical impactor (Precision Systems [Horsham, PA]
model TBI 0310) (moderate TBI). After 3 months, all rats
were killed by transcardiac perfusion with ice-cold saline after
intraperitoneal injection with a lethal dose of Euthanyl. Six
brains were drop-ﬁxed in ice cold Bouin ﬁxative (ThermoFisher) for immunohistochemical analysis while 6 were frozen
on dry ice for neurochemical analysis. Bouin ﬁxative was used

Immunohistochemistry in CTE cases
pThr175, pThr231, and T22 immunoreactivity was observed in
the hippocampal formation in all cases of CTE and CTE-ALS
(table 1, ﬁgure 2A). This included tau-immunoreactive neuroﬁbrillary tangles (NFTs) and dystrophic neurites throughout the CA1–4 regions and extending into the entorhinal
cortex in all cases. Consistent with the limited pThr175 tau
non-neuronal pathology observed previously,10 oligodendroglial tau immunoreactivity was observed to a limited extent
in 5 cases only.10 When present in control cases (3/5), tau
immunoreactivity was observed only as faint immunoreactive

Neurology | Volume 90, Number 5 | January 30, 2018

Results
Western blot of human CTE
Insoluble tau protein isolated from CTE cases contained all 6
isoforms in both phosphorylated and dephosphorylated isolates. This was in contrast to the 3 isoforms constituting the
paired helical ﬁlament motif in the insoluble fraction observed
in a control AD case (ﬁgure 1).20

Neurology.org/N

Figure 1 Tau isoform characterization

Representative Western blot of chronic
traumatic
encephalopathy
(CTE)–
derived fractionated tau protein shows
all 6 tau isoforms in the insoluble fraction
in distinction to the 3-isoform, paired
helical filament (PHF) motif observed in
Alzheimer disease (AD). (Probed with
mouse anti-T14/T46 total tau antibody;
blots shown are from the same case on 2
separate blots.)

punctate neuronal staining in the absence of NFTs (ﬁgure 2B).
No neuritic pathology was observed in controls.
We also observed pathologic tau deposition within the spinal
cord regardless of the tau phosphoepitope studied (ﬁgure
2B). The presence of tau pathology was independent of
whether the underlying pathologic diagnosis was CTE or
CTE-ALS (table 1) and consisted of sparsely distributed
NFTs in motor neurons and dystrophic neurites. In all cases,
pathologic inclusions were minimal in number relative to
a more diﬀuse immunoreactivity to pThr231 tau and pThr175
tau. No pThr175 tau staining was observed in control motor
neurons, whereas pThr231 tau was observed, but when present, only as diﬀuse perikaryal staining of motor neurons.
Lipofuscin staining was observed in some controls.
Table 1 Hippocampal and spinal cord pathology
summary
Antibody

CTE

CTE-ALS

Control

Hippocampus semiquantitation (case-positive ratios)
pThr175

++++ (5/5)

+++−++++ (5/5)

+−++ (3/5)

pThr231

++++ (5/5)

+++−++++ (5/5)

±−+ (3/5)

T22

++++ (5/5)

±−+++ (5/5)

±−+ (3/5)

Spinal cord pathology case-positive ratios
pThr175

3/5

3/5

0/5

pThr231

4/5

4/5

2/5

T22

4/5

1/5

0/5

Abbreviations: ALS = amyotrophic lateral sclerosis; CTE = chronic traumatic
encephalopathy.
The semiquantitative scale was applied to the field of interest as visualized
under a 20× objective with the neuronal pathology quantified as follows: − =
none; ± = fewer than 5 inclusions; + = fewer than 10 inclusions; ++ = more
than 20 inclusions with scattered distribution; +++ = more than 20 inclusions
but with locally dense distribution; ++++ = more than 20 inclusions with
a diffuse distribution.

Neurology.org/N

We observed a shift in the pattern of immunoreactivity of
pGSK3β from primarily nuclear as observed in the control
cases to a diﬀusely cytosolic pattern (ﬁgure e-1, http://links.
lww.com/WNL/A98). This pattern was observed in hippocampal CA2 and spinal cord motor neurons in all CTE cases
while only being present in occasional isolated cells in
controls.
Double-immunolabeling of the hippocampus for both
pThr175 tau and pThr231 tau consistently demonstrated
colocalization of immunoreactivity to pThr175 with pThr231
immunoreactivity. However, the converse was not observed
in that not all pThr231 tau immunoreactive hippocampal
neurons were also pThr175-positive, suggesting that only
a subset of pThr231 tau pathology is also pThr175-positive.10
This is consistent with our previous observations.10 We also
observed colocalization of pThr231 tau and T22 (oligomerized
tau), suggesting that oligomeric tau was a component of
pThr231 tau pathology. Due to the nature of the antibodies, it
was not possible to test for colocalization of pThr175 with T22
as they were raised in the same species, not puriﬁed and not
compatible with the primary antibody labeling system available to us. While we can therefore only infer that pThr175 tau
protein colocalizes with oligomeric tau as well, this inference
is supported by our previous studies of a range of tauopathies
in which serial sections were available for analysis.10 The inference is further supported by our ﬁnding that pThr175 tau
immunoreactivity consistently colocalized with active GSK3β
(ﬁgure 3).
pThr175 and pThr231 expression in moderate TBI
Both pThr175 and pThr231 tau neuronal immunoreactivity was
observed in moderate TBI rat brains (ﬁgure 4). Of note,
pThr175-positive neuronal staining was observed in regions
distant to the injury site mainly as axonal staining; however,
no ﬁbrillar inclusion-type pathology was observed in regions
distant from the injury site. While pThr175 tau expression was
elevated within the hemisphere ipsilateral to the injury,
Neurology | Volume 90, Number 5 | January 30, 2018
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Figure 2 Tau pathology in hippocampus and ventral horn in chronic traumatic encephalopathy (CTE) and CTE–
amyotrophic lateral sclerosis (ALS)

(A) Low-magnification (4× objective) composites of whole
hippocampus stained for tau phosphorylated at threonine 175 (pThr175 tau) in CTE and control (inlay is CA2
region taken with 40× objective, scale bar = 50 μm). CA1 =
CA1 region; CA3 = CA3 region; DG = dentate gyrus; sub =
subiculum (composite image based on images taken with
a 4× objective). Note the presence of prominent tau immunoreactivity in CA1 through CA4, extending into the
entorhinal cortex. (B) Representative tau pathology observed in both the hippocampus (CTE case) and ventral
horn of the spinal cord (CTE-ALS) when probed by rabbit
anti-pThr175 tau, rabbit anti–tau phosphorylated at
231
threonine 231 (pThr
tau), or rabbit anti-T22 (tau oligomer) antibodies. Images taken with 100× objective
(scale bar = 20 μm).

pThr175 tau expression in the contralateral hemisphere, while
appearing to be increased, was not diﬀerent from controls
when normalized against total tau (p = 0.05 and 0.065, respectively, one-way ANOVA with p = 0.008 and F = 5.757).
Diﬀuse pThr231 staining was observed in healthy neurons. In
contrast, pThr231 tau immunoreactive pathology was only
observed near the site of injury.
We investigated tau protein phosphorylation and GSK3β
activation by western blot (ﬁgure 4C). pTyr216 GSK3β was
elevated in ipsilateral and contralateral hemispheres relative to
uninjured controls (p = 0.005 and 0.001, respectively, oneway ANOVA with p < 0.001 and F = 13.928) when normalized against total GSK3β (ﬁgure 4). Finally, we observed the
same change in localization of pGSK3β in moderate TBI rat
brains as in CTE cases. This was quantiﬁed by blinded counts
in which we observed an increase in diﬀuse expression of
pTyr216 GSK3β in the injured hemisphere compared to uninjured control rats (p = 0.01 by Tukey post hoc test after oneway ANOVA p = 0.004 and F = 7.559; ﬁgure e-2, http://links.
lww.com/WNL/A98).
e384
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Discussion
We have observed that both CTE and CTE-ALS are tauopathies in which pathologic tau aggregates contain aberrantly phosphorylated tau with immunoreactivity to both
pThr175 tau and pThr231 tau. The presence of T22 immunoreactivity (recognizing oligomeric tau) is consistent with
a pivotal role for phosphorylation at Thr175 in the pathogenesis of CTE and CTE-ALS. The inference can be made
on the basis of our previous study, which showed that
pThr175 tau pathology only occurs in pathologic conditions
and that the expression of pThr175 tau coincides with oligomerized tau in the same neuronal populations, as does the
presence of pThr231.10 Of note, this pathologic process of tau
phosphorylation can be triggered experimentally in an in
vivo model of moderate TBI and is consistent with a previously reported tauopathy induced by repeated trauma in
a murine model of TBI, although this latter study did not
investigate the physicochemical properties of the tauopathy.24 The ﬁnding that the tauopathy of CTE and CTE-ALS
consists of the expression of all 6 tau isoforms in both the
Neurology.org/N

Figure 3 Colocalization of tau phosphorylated at threonine 175 (pThr175 tau) and tau phosphorylated at threonine 231
(pThr231 tau)

Hippocampal neurons in chronic traumatic encephalopathy (CTE) (upper panels) demonstrate colocalization of pThr175 tau and pThr231 tau. The presence of
pathologic tau oligomers (T22 immunoreactivity) was colocalized to pThr231 tau-immunoreactive neurons in CTE (middle panels). Consistent with a role in
activation of glycogen synthase kinase–3β (GSK3β) in inducing pathologic tau deposition, we observed the colocalization of pThr175tau with the active pGSK3β
immunoreactivity (lower panel). Tissues were immunolabeled with rabbit anti-pThr175 tau, rabbit anti-pThr231 tau, rabbit anti-T22 antibody, and mouse antiGSK3β pTyr216 antibody. For double-labeled tissue, red channel antibodies were labeled directly with Alexa Fluor 555. Scale bar = 5 μm.

soluble and insoluble tau isolates conﬁrms that this process is
biochemically distinct from the tauopathy of AD.
Consistent with our previous reports, pThr175 tau staining was
only observed when other pathologic tau markers were also
present10 and as such, pThr175 tau-positive staining in controls
was restricted to those individuals with advanced age, where
some tau pathology is expected in the hippocampal formation.25 Therefore, pThr175 tau appears to also be an indicator
of toxicity and neuronal damage across a broad range of
tauopathies and should be considered in future studies as
a CSF or blood biomarker in the diagnosis of CTE26 either
alone or in combination with other markers of neuronal injury
such as 14-3-327 or neuroﬁlament proteins.28

observed in the soluble and insoluble tau isolates is in distinction to that observed in a number of tauopathies, including AD (in which the pathogenic tau marker is the PHF
triplet), corticobasal degeneration and progressive supranuclear palsy (4R tauopathies), and Pick disease (3R
tauopathy).29–31 This could be interpreted as indicative that
the tauopathy of CTE, CTE-ALS, and ALSci is a secondary
event triggered in response to a primary neuronal injury. In
both CTE and CTE-ALS, this can be postulated to be directly
due to the TBI itself, a hypothesis that is supported by the in
vivo moderate TBI experimental paradigm. While the trigger
for the tauopathy of ALSci remains unknown, it is clear that
once initiated, the presence of pThr175 leads to a cascade of
events that culminates in neuronal death in vitro.16,32

The tau isoform composition proﬁle observed in CTE in this
study and previously in ALSci20 in which all 6 tau isoforms are

In relationship to our understanding of the pathophysiology
of ALS, 4%–6% of patients with CTE also develop ALS

Neurology.org/N
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Figure 4 Tau phosphorylated at threonine 175 (pThr175 tau) pathology in moderate traumatic brain injury (TBI)

At 3 months following moderate TBI, pThr175 tau pathology was observed. (A) Composite images of whole brain sections stained for pThr175 tau. Images were
taken with a 4× objective. Inlay image taken with 40× objective. Arrow denotes site of injury. CA1 = CA1 region; CA3 = CA3 region; DG = dentate gyrus. Scale bar =
50 μm. (B) High-magnification images with moderate TBI show neuronal and neuritic pathology. Images were taken with 100× objective. Scale bar = 20 μm. (C)
Western blots of pThr175 tau and total tau in ipsilateral and contralateral brain injuries. (D) Densitometry of western blots probed for pThr175 tau and total tau
(pThr175/total tau). (E) pTyr216 glycogen synthase kinase–3β (GSK3β) and total GSK3β (pTyr216/total GSK3β) in ipsilateral and contralateral brain injuries. (F)
Densitometry of western blots probed for pTyr216 GSK3β and total GSK3β. *p < 0.05. Contra = contralateral injury hemisphere; Ipsi = ipsilateral injury hemisphere.

(CTE-ALS),7 a rate much higher than the incidence of ALS
(2–3 per 100,000) in the general population.9 Unique to
motor neuron degeneration associated with CTE-ALS is tau
pathology in the spinal cord. The only other instance of
a disseminated tauopathy in association with motor neuron
degeneration is that observed in the previously hyperendemic Western Paciﬁc variant of ALS, a variant of ALS
recognized to be at the intersection of an environmental
insult in an at-risk population.33,34
While we have observed pathologic tau phosphorylation in
the spinal cords of both patients with CTE and patients with
CTE-ALS in this study, the variability observed warrants investigation on a larger cohort of cases with detailed rostrocaudal analysis to discern whether there is a correlation
between motor symptom progression and regional tau deposition. We could not undertake such an analysis given the
nature of tissue selection (cervical, thoracic, or lumbar for
diﬀerent cases). However, the absence of tau deposition in the
spinal cords of patients with sporadic ALS suggests that the
spinal motor neuron tauopathy of CTE-ALS is not an incidental ﬁnding or secondary to the primary neuronal injury
of ALS. It is possible that tau protein phosphorylation and
pathology begins early in the neurodegenerative process in
e386
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CTE or CTE-ALS, in which case spinal cord pathology would
be expected to precede symptom onset in patients who would
otherwise develop motor impairment. In addition, given
previous reports of TDP-43 deposition in the spinal cord of
CTE-ALS,9 a much larger study investigating the correlation
of TDP-43-positive neuronal cytoplasmic inclusions is required to bring clarity to the contributing pathologies concomitant to motor neuron death.
In these studies, we have observed pThr175 tau, in conjunction
with pThr231 tau, oligomerized tau, and changes in active GSK3β
localization consistent with a pathologic tauopathy driven by the
aberrant phosphorylation of Thr175 tau in CTE and CTE-ALS.
While we have shown that moderate TBI can directly drive this
process, understanding how this induces pThr175 is the topic of
current studies. Given our previous ﬁndings that this pathologic
cascade of tau phosphorylation can be fully inhibited, and that
this inhibition abolishes pThr175 tau-induced neuronal death,16
our work suggests that both CTE and CTE-ALS may be amenable to pharmacologic inhibition of GSK3β activation.
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Study question
Are pathologic tau phosphorylation and glycogen synthase
kinase-3β (GSK3β) activation observed in chronic traumatic
encephalopathy (CTE) and CTE with amyotrophic lateral
sclerosis (CTE-ALS), and can this be replicated in an experimental model of moderate traumatic brain injury (mTBI)?
Summary answer
Pathologic tau phosphorylation and GSK3β activation are
observed in CTE, CTE-ALS, and modeled mTBI.
What is known and what this article adds
Pathologic tau phosphorylation and GSK3β activation occur in
ALS with cognitive impairment (ALSci). By showing that they
also occur in CTE and CTE-ALS, this study suggests that CTE
and CTE-ALS may share pathophysiologic features with ALSci.
Participants and setting
This study analyzed samples from 6 patients with stage III
CTE for Western blotting experiments. For further experiments, the study analyzed samples from 5 patients with
CTE, 5 patients with CTE-ALS, and 5 healthy controls. All
samples were obtained from the Veterans Aﬀairs–Boston
University–Concussion Legacy Foundation brain bank.
Design, size, and duration
Western blotting was used to analyze total tau isoform expression in anterior cingulate and temporal pole samples from the
patients with stage III CTE. Immunohistochemistry was used to
analyze the expression of phosphorylated or oligomeric tau and
activated GSK3β in hippocampal and spinal cord samples from
the other participants. Tau pathology and GSK3β activation
were also evaluated at 3 months after experimental mTBI.
Primary outcomes
The primary outcomes were detecting Thr175-phosphorylated
tau, Thr231-phosphorylated tau, oligomeric tau, and Tyr216phosphorylated GSK3β.
Main results and the role of chance
The isolates from the 6 patients with stage III CTE contained
all 6 tau isoforms in both phosphorylated and dephosphorylated states. Thr175-phosphorylated, Thr231-phosphorylated,

and oligomeric tau were observed in all hippocampal and spinal
cord samples from patients with CTE or CTE-ALS. They were
observed in hippocampal samples from 3 of the 5 healthy
controls, but only faintly. Thr231-phosphorylated tau was diffusively observed in spinal cord samples from the healthy
controls. Cytosolic diﬀusion of Tyr216-phosphorylated GSK3β
was observed in hippocampal CA2 and spinal cord motoneurons from all patients with CTE or CTE-ALS but only
occasionally observed in samples from the healthy controls.
Three months following experimental mTBI, increased levels
of Thr175-phosphorylated tau and activated GSK3β were observed in association with tau neuronal pathology.
Bias, confounding, and other reasons
for caution
This study included a small number of participants.
Generalizability to other populations
This study’s observations for CTE-ALS may not be generalizable to ALS without CTE, as only one other ALS subtype,
one speciﬁc to the Western Paciﬁc, features disseminated
tauopathy in association with motor neuron degeneration.
Study funding/potential competing interests
This study was funded by the Ontario Neurodegenerative
Disease Research Initiative and the Windsor–Essex ALS Society. The authors report no competing interests. Go to
Neurology.org/N for full disclosures.
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